Well, if anything, the shareholder update by September 1st...

Well, if anything, the shareholder update by September 1st should - I hope - stabilize things for a bit. But it will be awhile before things pick up for Novogen. There just isn't any volume, especially on the US side of the equation.

Things that may give a boost: 1) Announcement of new CEO, 2) Orphan Indication for Cantrixil and Anisina, 3) Trilexium getting Orphan Designation. I doubt, but would be pleasantly surprised, that an announcement of entry into Phase 1 will give it any meaningful boost. Anecdotally, I haven't seen any boost in price or activity for entering into Phase 1 with pharmaceuticals. And from a correspondence with Ms. Robins, it doesn't appear that Cantrixil or Anisina will go into clinicals until early 2016; further, they presently don't have enough data to get orphan indications for Cantrixil nor Anisina.

Can't even tell if we've hit bottom yet. There just isn't enough volume to support a significant indication that it has. Hoping for the best. GLTA.